Mesoblast Limited
MSB.AXHealthcareASXBiotechnology
Scan Results
Daily timeframeMesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. With a market capitalization of $2.73B, it sits in mid-cap territory. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Market Cap
$2.73B
Beta
0.79
P/E (TTM)
—
P/E (Fwd)
42.81
EPS (TTM)
$-0.10
EPS (Fwd)
$0.05
ROE
-18.2%
ROA
-6.2%
Cash
$130.0M
Total Debt
$135.1M
Free CF
-$69.4M
52W Change
34.2%
Annual Financials
Cash vs Debt
Mesoblast Limited carries $135.1M in total debt against $130.0M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$69.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -18.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $10.2M to $17.2M.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Mesoblast Limited and its sector.